598 related articles for article (PubMed ID: 24904092)
1. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.
Irazabal MV; Rangel LJ; Bergstralh EJ; Osborn SL; Harmon AJ; Sundsbak JL; Bae KT; Chapman AB; Grantham JJ; Mrug M; Hogan MC; El-Zoghby ZM; Harris PC; Erickson BJ; King BF; Torres VE;
J Am Soc Nephrol; 2015 Jan; 26(1):160-72. PubMed ID: 24904092
[TBL] [Abstract][Full Text] [Related]
2. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.
Irazabal MV; Abebe KZ; Bae KT; Perrone RD; Chapman AB; Schrier RW; Yu AS; Braun WE; Steinman TI; Harris PC; Flessner MF; Torres VE;
Nephrol Dial Transplant; 2017 Nov; 32(11):1857-1865. PubMed ID: 27484667
[TBL] [Abstract][Full Text] [Related]
3. Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan.
Higashihara E; Horie S; Muto S; Kawano H; Tambo M; Yamaguchi T; Taguchi S; Kaname S; Yokoyama K; Yoshioka T; Furukawa T; Fukuhara H
Am J Nephrol; 2020; 51(11):881-890. PubMed ID: 33227802
[TBL] [Abstract][Full Text] [Related]
4. Validation of the Mayo Imaging Classification System for Predicting Kidney Outcomes in ADPKD.
Bais T; Geertsema P; Knol MGE; van Gastel MDA; de Haas RJ; Meijer E; Gansevoort RT;
Clin J Am Soc Nephrol; 2024 May; 19(5):591-601. PubMed ID: 38407866
[TBL] [Abstract][Full Text] [Related]
5. Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases.
Higashihara E; Yamamoto K; Kaname S; Okegawa T; Tanbo M; Yamaguchi T; Shigemori K; Miyazaki I; Yokoyama K; Nutahara K
Clin Exp Nephrol; 2019 Jan; 23(1):100-111. PubMed ID: 30097754
[TBL] [Abstract][Full Text] [Related]
6. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.
Kline TL; Korfiatis P; Edwards ME; Bae KT; Yu A; Chapman AB; Mrug M; Grantham JJ; Landsittel D; Bennett WM; King BF; Harris PC; Torres VE; Erickson BJ;
Kidney Int; 2017 Nov; 92(5):1206-1216. PubMed ID: 28532709
[TBL] [Abstract][Full Text] [Related]
7. The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD.
Lavu S; Vaughan LE; Senum SR; Kline TL; Chapman AB; Perrone RD; Mrug M; Braun WE; Steinman TI; Rahbari-Oskoui FF; Brosnahan GM; Bae KT; Landsittel D; Chebib FT; Yu AS; Torres VE; ; Harris PC
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32634120
[TBL] [Abstract][Full Text] [Related]
8. Predicting Future Renal Function Decline in Patients with Autosomal Dominant Polycystic Kidney Disease Using Mayo Clinic Classification.
Borrego Utiel FJ; Esteban de la Rosa RJ; Merino García E; Medina Benítez A; Polo Moyano A; Moriana Domínguez C; Morales García AI; Bravo Soto JA
Am J Nephrol; 2021; 52(8):630-641. PubMed ID: 34518464
[TBL] [Abstract][Full Text] [Related]
9. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
Messchendorp AL; Meijer E; Visser FW; Engels GE; Kappert P; Losekoot M; Peters DJM; Gansevoort RT;
Am J Nephrol; 2019; 50(5):375-385. PubMed ID: 31600749
[TBL] [Abstract][Full Text] [Related]
10. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.
Yu ASL; Shen C; Landsittel DP; Harris PC; Torres VE; Mrug M; Bae KT; Grantham JJ; Rahbari-Oskoui FF; Flessner MF; Bennett WM; Chapman AB;
Kidney Int; 2018 Mar; 93(3):691-699. PubMed ID: 29290310
[TBL] [Abstract][Full Text] [Related]
11. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
Chebib FT; Torres VE
Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and disease predictors of a large Chinese cohort of patients with autosomal dominant polycystic kidney disease.
Chen D; Ma Y; Wang X; Yu S; Li L; Dai B; Mao Z; Sun L; Xu C; Rong S; Tang M; Zhao H; Liu H; Serra AL; Graf N; Liu S; Wüthrich RP; Mei C
PLoS One; 2014; 9(3):e92232. PubMed ID: 24651850
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
Chonchol M; Gitomer B; Isakova T; Cai X; Salusky I; Pereira R; Abebe K; Torres V; Steinman TI; Grantham JJ; Chapman AB; Schrier RW; Wolf M
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1461-1469. PubMed ID: 28705885
[TBL] [Abstract][Full Text] [Related]
14. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Bae KT; Baumgarten DA; Kenney PJ; King BF; Glockner JF; Wetzel LH; Brummer ME; O'Neill WC; Robbin ML; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
Kidney Int; 2003 Sep; 64(3):1035-45. PubMed ID: 12911554
[TBL] [Abstract][Full Text] [Related]
15. Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.
Brosnahan GM; Abebe KZ; Rahbari-Oskoui FF; Patterson CG; Bae KT; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC; Perrone RD; Steinman TI; Torres VE;
Curr Hypertens Rev; 2017; 13(2):109-120. PubMed ID: 28460625
[TBL] [Abstract][Full Text] [Related]
16. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
Bennett H; McEwan P; Hamilton K; O'Reilly K
BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.
Brosnahan GM; Abebe KZ; Moore CG; Rahbari-Oskoui FF; Bae KT; Grantham JJ; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Miskulin DC; Steinman TI; Torres VE;
Am J Kidney Dis; 2018 May; 71(5):666-676. PubMed ID: 29306517
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.
Torres VE; King BF; Chapman AB; Brummer ME; Bae KT; Glockner JF; Arya K; Risk D; Felmlee JP; Grantham JJ; Guay-Woodford LM; Bennett WM; Klahr S; Meyers CM; Zhang X; Thompson PA; Miller JP;
Clin J Am Soc Nephrol; 2007 Jan; 2(1):112-20. PubMed ID: 17699395
[TBL] [Abstract][Full Text] [Related]
19. Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease.
Bae KT; Shi T; Tao C; Yu ASL; Torres VE; Perrone RD; Chapman AB; Brosnahan G; Steinman TI; Braun WE; Srivastava A; Irazabal MV; Abebe KZ; Harris PC; Landsittel DP;
J Am Soc Nephrol; 2020 Jul; 31(7):1640-1651. PubMed ID: 32487558
[TBL] [Abstract][Full Text] [Related]
20. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.
Gansevoort RT; Hariri A; Minini P; Ahn C; Chapman AB; Horie S; Knebelmann B; Mrug M; Ong ACM; Pei YPC; Torres VE; Modur V; Antonshchuk I; Perrone RD
Am J Kidney Dis; 2023 May; 81(5):517-527.e1. PubMed ID: 36535535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]